登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《bioRxiv，6月20日，Engineered human mesenchymal stem cells as new vaccine platform for COVID-19》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-06-22

  • Engineered human mesenchymal stem cells as new vaccine platform for COVID-19

    Junhua Liu, Huping Jiao, View ORCID ProfileXiushan Yin

    doi: https://doi.org/10.1101/2020.06.20.163030

    Abstract

    Recently, there are several routes for COVID-19 vaccine research, yet their weaknesses lie in low efficiency, tolerability, immune adaptability and safety. We describe a new approach to COVID-19 based on engineered human mesenchymal stem cells (hu-MSC), which is like a small protein antigen response device, but will be gradually cleared and degraded by body' s immune system among recognization process. The antibody response results show that this is effective and fast. Furthermore, after several antibody response tests, we obtained an injection of a set of cocktail-like modified human mesenchymal stem cell line. This strategy opened a new avenue for vaccine design against COVID-19.

  • 原文来源：https://www.biorxiv.org/content/10.1101/2020.06.20.163030v1
10浏览量
原文链接
相关报告

  • 《ChinaXiv，2月27日，Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-02-29
    • Background The COVID-19 cases increased very fast in the last two months. The mortality among critically ill patients, especially the elder ones, was relatively high. Considering that most of the dead patients were caused by severe inflammation response, it is very urgent to develop effective therapeutic agents and strategies for these patients. The human umbilical cord mesenchymal stem cells (hUCMSCs) have shown very good capability to modulate immune response and repair the injured tissue with good safety. Case Presentation Here, we reported the treatment process and clinical outcome of a 65-year-old female critically ill COVID-19 patient infected with 2019-nCoV (now called SARS-CoV-2). The significant clinical outcome and well tolerance was observed by the adoptive transfer of allogenic hUCMSCs. Conclusions Our results suggested that the adoptive transfer therapy of hUCMSCs might be an ideal choice to be used or combined with other immune modulating agents to treat the critically ill COVID-19 patients. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    19浏览量
    原文链接

  • 《bioRxiv，6月20日，Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-06-22
    • Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19 View ORCID ProfileSimon P Graham, View ORCID ProfileRebecca K McLean, View ORCID ProfileAlexandra J Spencer, View ORCID ProfileSandra Belij-Rammerstorfer, Daniel Wright, Marta Ulaszewska, Jane C Edwards, Jack W P Hayes, Veronica Martini, Nazia Thakur, doi: https://doi.org/10.1101/2020.06.20.159715 Abstract Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replication-deficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein was initiated in April 2020 following non-human primate studies using a single immunisation. Here, we compared the immunogenicity of one or two doses of ChAdOx1 nCoV-19 in both mice and pigs. Whilst a single dose induced antigen-specific antibody and T cells responses, a booster immunisation enhanced antibody responses, particularly in pigs, with a significant increase in SARS-CoV-2 neutralising titres.
    49浏览量
    原文链接